In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Principia Biopharma Inc.

www.principiabio.com

Latest From Principia Biopharma Inc.

Deal Watch: Celgene Joins Line Of Partners Tapping Exscientia’s AI-Driven Discovery Engine

While the proposed Bristol/Celgene merger nears an April vote, Celgene continues a recent spate of deal-making, paying $25m up front to Exscientia to discover small molecule candidates for cancer and autoimmune disease.

Business Strategies Commercial

Follow The Money, An Interactive Biotech Financing Map

In 2018, while biotech venture activity spoke mainly with an American accent, China emerged as the world’s third most active cluster, while the UK led the way in Europe.

Commercial Financing

IPO Update: Returns Sag As Seven More Biopharmas Go Public In September

The average return for the 54 drug developers that went public in the US during first three quarters of 2018 was 13.6% as of Oct. 1 versus 16.9% as of Aug. 31 for the 47 biopharma firms that launched IPOs during the first eight months of this year. September had seven new offerings after just two in August.

Financing Business Strategies

Finance Watch: Lilly Completes Elanco Animal Health Spin-Out As New IPO Filings Keep Rising

Public Company Edition: Eli Lilly & Co. wasted no time spinning out its animal health business Elanco, which raised $1.5bn in its public debut. Also, as the biopharma IPO tally rises, Vivo Capital launches a new public life science company fund. Meanwhile, Concordia completes its recapitalization.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Dermatology
  • Immune Disorders
  • Inflammation
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Principia Biopharma Inc.
  • Senior Management
  • Martin Babler, CEO
    Christopher Y Chai, CFO
    David Goldstein, PhD, CSO
    Roy Hardiman, CBO
    Dolca Thomas, MD, CMO
  • Contact Info
  • Principia Biopharma Inc.
    Phone: (650) 416-7700
    220 E. Grand Ave.
    South San Francisco, CA 94080
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register